Study of Medtronic, Inc. (MDT) Endeavor® Drug-Eluting Stent Demonstrates Long-Term Advantages over Taxus® DES  
11/9/2011 10:16:24 AM

SAN FRANCISCO--(BUSINESS WIRE)--New research findings released at TCT 2011 show that the Endeavor® zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed Boston Scientific Corp.’s Taxus® paclitaxel-eluting stent on standard measures of safety and efficacy through five years of clinical follow-up.